Beryl Drugs Q1 FY27 revenue up 167% YoY, profit jumps tenfold

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹22.30

prior close

₹24.70

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+4.4% vs market

Pharmaceuticals peers, median of 165sector-0.6%+5.4% vs sector

On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.0

15m

-2.8

30m

-2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8+0.4+4.4-0.6+5.4

Next day

+1.1+0.5+0.6-0.3+1.4

+2.9+0.6+2.3-0.7+3.6

+3.1+0.7+2.4-1.4+4.6

+3.1+1.1+2.0-1.1+4.2

-1.3+0.5-1.8-2.0+0.7

+2.2+1.3+0.9-1.4+3.7

15d

+9.6+0.5+9.1-1.0+10.6

+4.2-0.8+5.1-0.4+4.6

+14.3-0.9+15.2-3.2+17.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs reported Q1 FY27 revenue of Rs 756.63 lakhs, up 167% YoY from Rs 283.58 lakhs and about 38% QoQ. Net profit surged to Rs 22.08 lakhs from Rs 2.11 lakhs YoY. EPS stood at Rs 0.47 versus Rs 0.04 last year. Auditor issued an unqualified review report.

Likely market impact

Strong topline and bottomline growth signals improving business momentum; small-cap pharma may see positive investor sentiment.